Large companies, particularly global pharmaceutical businesses, are increasingly willing to initiate antitrust litigation, according to Brian Savage, vice president and general counsel of generic drug giant Teva Pharmaceuticals.

Speaking at Dechert’s annual antitrust event, revived Tuesday in Philadelphia after a three-year pandemic-induced hiatus, Savage highlighted a number of issues occupying the lawyers at major enterprises like Teva given a growing globalized network of antitrust and intellectual property regulation and litigation.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]